Bristol-Myers Squibb (NYSE:BMY - Free Report) - Stock analysts at William Blair reduced their Q2 2025 EPS estimates for Bristol-Myers Squibb in a research report issued on Friday, April 25th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings per share of $1.52 for the quarter, down from their previous forecast of $1.57. William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for Bristol-Myers Squibb's current full-year earnings is $6.74 per share. William Blair also issued estimates for Bristol-Myers Squibb's Q3 2025 earnings at $1.87 EPS, FY2025 earnings at $6.77 EPS, Q1 2026 earnings at $1.53 EPS, Q2 2026 earnings at $1.50 EPS, Q4 2026 earnings at $1.41 EPS, FY2026 earnings at $6.18 EPS and FY2027 earnings at $6.26 EPS.
BMY has been the subject of a number of other research reports. Jefferies Financial Group decreased their target price on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. The Goldman Sachs Group restated a "neutral" rating and issued a $55.00 target price (down previously from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. UBS Group cut their price target on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday, April 11th. Truist Financial increased their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Finally, Citigroup lifted their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Bristol-Myers Squibb has a consensus rating of "Hold" and an average price target of $58.00.
View Our Latest Stock Analysis on BMY
Bristol-Myers Squibb Stock Up 0.8 %
Shares of NYSE BMY traded up $0.42 during mid-day trading on Monday, reaching $50.03. The company had a trading volume of 2,138,215 shares, compared to its average volume of 12,931,534. The stock has a fifty day moving average of $55.83 and a two-hundred day moving average of $56.39. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33. The company has a market capitalization of $101.81 billion, a price-to-earnings ratio of -11.33, a PEG ratio of 2.07 and a beta of 0.41. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25.
Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The company's revenue was down 5.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($4.40) earnings per share.
Institutional Investors Weigh In On Bristol-Myers Squibb
Several large investors have recently modified their holdings of the stock. Truist Financial Corp lifted its holdings in shares of Bristol-Myers Squibb by 3.9% during the fourth quarter. Truist Financial Corp now owns 1,597,150 shares of the biopharmaceutical company's stock valued at $90,335,000 after acquiring an additional 60,365 shares during the period. Contravisory Investment Management Inc. bought a new position in Bristol-Myers Squibb during the 4th quarter valued at about $488,000. Inspire Trust Co. N.A. boosted its position in Bristol-Myers Squibb by 39.0% in the third quarter. Inspire Trust Co. N.A. now owns 103,500 shares of the biopharmaceutical company's stock valued at $5,355,000 after buying an additional 29,044 shares in the last quarter. Versant Capital Management Inc grew its stake in Bristol-Myers Squibb by 14.0% during the fourth quarter. Versant Capital Management Inc now owns 78,690 shares of the biopharmaceutical company's stock worth $4,451,000 after buying an additional 9,692 shares during the last quarter. Finally, Decker Retirement Planning Inc. acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $474,000. 76.41% of the stock is currently owned by institutional investors.
Insider Buying and Selling at Bristol-Myers Squibb
In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of the company's stock in a transaction that occurred on Friday, April 25th. The stock was purchased at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the transaction, the executive vice president now directly owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This trade represents a 5.36 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.09% of the company's stock.
Bristol-Myers Squibb Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were paid a dividend of $0.62 per share. The ex-dividend date was Friday, April 4th. This represents a $2.48 annualized dividend and a yield of 4.96%. Bristol-Myers Squibb's dividend payout ratio is 92.88%.
About Bristol-Myers Squibb
(
Get Free Report)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Featured Articles
Before you consider Bristol-Myers Squibb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol-Myers Squibb wasn't on the list.
While Bristol-Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
